Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
EyePoint Pharmaceuticals
Pharma
EyePoint phase 3 for AMD disappoints, tanking stock
EyePoint turned to an ad hoc analysis in an effort to salvage the tyrosine kinase inhibitor’s performance in a phase 3 trial.
Donavyn Coffey
Aug 17, 2026 3:30pm
EyePoint sues Ocular for defamation in retina drug race
Mar 23, 2026 11:40am
EyePoint scopes out new commercial chief to prep Duravyu launch
Feb 18, 2026 7:00am
EyePoint's Duravyu bounces back with promising DME data
Oct 28, 2024 1:11pm
EyePoint's Yutiq production lands in the FDA's crosshairs
Aug 27, 2024 4:07pm
EyePoint reports Duravyu trial fail, raising questions
May 6, 2024 10:55am
